Levosimendan may improve weaning outcomesin venoarterial ECMO patients

ASAIO Journal

Volumn 59, Issue 6, 2013, Pages 554-557

  Affronti, Alessandro ^a   Di Bella, Isidoro ^a   Carino, Davide ^a   Ragni, Temistocle ^a  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

ECMO; heart failure; levosimendan

Indexed keywords

ACTIVE METABOLITES; ECMO; EXTRACORPOREAL MEMBRANE OXYGENATION; HEART FAILURE; HEMODYNAMIC RESPONSE; LEVOSIMENDAN; MECHANICAL CIRCULATORY SUPPORT; OXYGEN CONSUMPTION;

RESPIRATORY THERAPY;

CARDIOLOGY;

ADRENALIN; DOBUTAMINE; LEVOSIMENDAN; NORADRENALIN;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; ASSISTED CIRCULATION; CARDIOGENIC SHOCK; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXTRACORPOREAL OXYGENATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SURVIVAL RATE;

CARDIOTONIC AGENTS; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; PYRIDAZINES; SHOCK, CARDIOGENIC; SURVIVAL RATE;

EID: 84887412588     PISSN: 10582916     EISSN: 1538943X     Source Type: Journal    
DOI: 10.1097/MAT.0b013e3182a4b32e     Document Type: Article

References (17)

1. Figgitt DP, Gillies PS, Goa KL: Levosimendan. Drugs 61: 613-627; discussion 628, 2001. (Pubitemid 32454527)
2. Shahzad GR, Benson SR: Levosimendan in cardiac surgery: Current best available evidence. Ann Thorac Surg 81: 1536-1546, 2006.
3. Sundberg S, Antila S, Scheinin H, Häyhä M, Virtanen M, Lehtonen L: Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals. Int J Clin Pharmacol Ther 36: 629-635, 1998. (Pubitemid 28562886)
4. Parissis JT, Adamopoulos S, Antoniades C, et al: Effects of levosimendan on proinflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 93: 1309-1312, 2004. (Pubitemid 38595693)
5. Ferroni R, Berger J, Schuette JJ: Management of the Cardiac ECMO patient, in Short BL (ed), ECMO Specialist Training Manual, 3rd ed. Ann Arbor, MI, ELSO, 2010, p. 147.
6. Lunghetti S, Palmerini E, Urselli R, et al: Effects of levosimendan without loading dose on systolic and diastolic function in patients with end-stage heart failure. Cardiol J 18: 532-537, 2011.
7. Packer M: REVIVE II: Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. Program and abstracts from the American Heart Association Scientific Sessions 2005; November 13-16, 2005; Dallas, TX, Late Breaking Clinical Trials II.
8. Mebazaa A, Cohen-Solal A, Kleber F, et al: Study design of a mortality trial with intravenous levosimendan (the SURVIVE study) in patients with acutely decompensated heart failure. Crit Care 8 (suppl 1): 87, 2004.
9. Levin R, Degrange M, Del Mazo C, Tanus E, Porcile R. Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Exp Clin Cardiol 17: 125-130, 2012.
10. Landoni G, Mizzi A, Biondi-Zoccai G, et al: Reducing mortality in cardiac surgery with levosimendan: A meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth 24: 51-57, 2010.
11. Maharaj R, Metaxa V: Levosimendan and mortality after coronary revascularization: A meta-analysis of randomized controlled studies. Crit Care 15: R140, 2011.
12. Eriksson HI, Jalonen JR, Heikkinen LO, et al: Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Ann Thorac Surg 87: 448-454, 2009.
13. Registry Report of the Extracorporeal Life Support Organization. Ann Arbor, MI, Extracorporeal Life Support Organization, 2011.
14. Wagner K, Risnes I, Abdelnoor M, Karlsen HM, Svennevig JL: Is it possible to predict outcome in cardiac ECMO? Analysis of preoperative risk factors. Perfusion 22: 225-229, 2007. (Pubitemid 350200807)
15. Hei F, Lou S, Li J, et al: Five-year results of 121 consecutive patients treated with extracorporeal membrane oxygenation at Fu Wai Hospital. Artif Organs 35: 572-578, 2011.
16. Conrad SA, Rycus PT, Dalton H: extracorporeal life support registry report 2004. ASAIO J 51: 4-10, 2005. (Pubitemid 40165243)
17. Combes A, Leprince P, Luyt CE, et al: Outcomes and long-term quality-of-life of patients supported by extracorporeal membrane oxygenation for refractory cardiogenic shock. Crit Care Med 36: 1404-1411, 2008. (Pubitemid 351620652)